While it has been hypothesized that high plaque stress and strain may be related to plaque rupture, its direct verification using in vivo coronary plaque rupture data and full 3-dimensional ...
The company highlighted active regulatory engagement with both the FDA and Japan’s PMDA, setting the stage for possible approval submissions in multiple geographies. Clinical trial data across both ...
Lantern Pharma Inc. (LTRN) reported its third-quarter 2025 earnings, showing a net loss of $4.2 million, or $0.39 per share, an improvement from the $4.5 million loss, or $0.42 per share, in the same ...
FDA feedback supports 2 potential registrational trials – 1) a registrational trial in 2nd line refractory BCG-unresponsive NMIBC, and 2) a randomized controlled trial in intermediate-risk NMIBC. FDA ...
fDepartment of Psychiatry and Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité–Universitätsmedizin Berlin, Berlin, Germany gGerman Center for Mental ...
We’ve all been there. You bought a top-rated smartphone, and at first, it worked flawlessly. But, over time, that device that once responded instantly to your touch starts to feel...sluggish.
These days, much online prose feels generic—flattened voice, repeated language, and similar punctuation. AI may now be infiltrating science journals These days, so much prose online is generic. There ...
Welcome to BioNTech's Third Quarter 2025 Earnings Call. I will now hand the call over to Doug Maffei, Vice President, Strategy and Investor Relations. Please go ahead. Thank you, operator. Good ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback